Li Jingyuan, Li Wei, Zhuang Liping
Beidahuang Group Mudanjiang Hospital, Mudanjiang, Heilongjiang, China.
Front Med (Lausanne). 2024 May 9;11:1385123. doi: 10.3389/fmed.2024.1385123. eCollection 2024.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by synovitis, leading to the destruction of articular cartilage and bone and ultimately resulting in joint deformity, loss of function, and a significant impact on patients' quality of life. Currently, a combination of anti-rheumatic drugs, hormonal drugs, and biologics is used to mitigate disease progression. However, conventional drug therapy has limited bioavailability, and long-term use often leads to drug resistance and toxic side effects. Therefore, exploring new therapeutic approaches for RA is of great clinical importance. Nanodrug delivery systems offer promising solutions to overcome the limitations of conventional drugs. Among them, liposomes, the first nanodrug delivery system to be approved for clinical application and still widely studied, demonstrate the ability to enhance therapeutic efficacy with fewer adverse effects through passive or active targeting mechanisms. In this review, we provide a review of the research progress on the targeting mechanisms of various natural biomimetic nano-delivery systems in RA therapy. Additionally, we predict the development trends and application prospects of these systems, offering new directions for precision treatment of RA.
类风湿性关节炎(RA)是一种慢性全身性自身免疫性疾病,主要特征为滑膜炎,可导致关节软骨和骨质破坏,最终造成关节畸形、功能丧失,并对患者生活质量产生重大影响。目前,抗风湿药物、激素类药物和生物制剂联合使用以减轻疾病进展。然而,传统药物治疗的生物利用度有限,长期使用常导致耐药性和毒副作用。因此,探索RA的新治疗方法具有重要的临床意义。纳米药物递送系统为克服传统药物的局限性提供了有前景的解决方案。其中,脂质体作为首个被批准用于临床应用且仍在广泛研究的纳米药物递送系统,通过被动或主动靶向机制展现出增强治疗效果且副作用较少的能力。在本综述中,我们综述了各种天然仿生纳米递送系统在RA治疗中的靶向机制研究进展。此外,我们预测了这些系统的发展趋势和应用前景,为RA的精准治疗提供新方向。